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Despite multimodal regimens and diverse treatment
options alleviating disease symptoms, morbidity and
mortality associated with advanced ischemic heart
failure remain high. Recently, technological innovation
has led to the development of regenerative therapeutic
interventions aimed at halting or reversing the vicious
cycle of heart failure progression. Driven by the unmet
patient need and fueled by encouraging experimental
studies, stem cell-based clinical trials have been
launched over the past decade. Collectively, these trials
have enrolled several thousand patients and
demonstrated the clinical feasibility and safety of cell-
based interventions. However, the totality of evidence
supporting their efficacy in ischemic heart failure
remains limited. Experience from the early randomized
stem cell clinical trials underscores the key points in trial
design ranging from adequate hypothesis formulation
to selection of the optimal patient population, cell type
and delivery route. Importantly, to translate the
unprecedented promise of regenerative biotherapies
into clinical benefit, it is crucial to ensure the
appropriate choice of endpoints along the regulatory
path. Accordingly, we here provide considerations
relevant to the choice of endpoints for regenerative
clinical trials in the ischemic heart failure setting.of regenerative interventions. These are guided byIntroduction
With the implementation of rapid coronary reperfusion
as a key interventional strategy, the prognosis of patients
with acute presentation of ischemic heart disease has
dramatically improved [1]. Yet, this success associated
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prevalence of chronic ischemic heart failure [2]. In-
deed, despite multiple treatment regimens, primarily
targeting symptom mitigation, the morbidity and mor-
tality of patients with advanced ischemic heart failure
have reached pandemic proportions. In an effort to
address the root cause of the problem, curative strat-
egies are increasingly being considered. A case in
point is the evolution of regenerative medicine tech-
nologies aiming to halt or even reverse progressive
organ deterioration in the setting of chronic heart
failure.
The prevailing unmet clinical need has provided a
major impetus for the development of clinically trans-
latable stem cell-based treatment algorithms, which
have shown encouraging results in experimental stud-
ies. In turn, this has led to a significant international
effort in stem cell-based clinical trials. Most clinical
trials have focused on stem cell application in acute/
subacute ischemic heart disease, targeting prevention
of heart failure induction [3]. Collectively, these trials
have demonstrated the clinical safety and feasibility of
cell-based interventions. However, experience is much
more limited in the setting of chronic, florid heart
failure [3–5]. To translate the promise of biotherapies
into clinical benefit, it is crucial to ensure the appro-
priate choice of endpoints along the regulatory path
recommendations of regulatory bodies, such as the
Food and Drug Administration (FDA) in the US or
the European Medicines Agency, that delineate gen-
eric and pathology-specific requirements as well as
rigorous criteria of good clinical practice and clinical
research. Here, we summarize the considerations rele-
vant to stages and settings of regenerative clinical tri-
als in chronic heart failure.le is distributed under the terms of the Creative Commons Attribution 4.0
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phase I/II heart failure stem cell trials
General principles
The regulatory and scientific principles and processes
utilized in the clinical development of cell therapy are
similar to those in more traditional drug trials. The
process for generating evidence on the safety and effect-
iveness of an intervention begins with phase I/II trials
which include a limited number of subjects. Pending the
feasibility and safety, initial trials may then progress to
confirmatory trials. The execution of phase I/II studies is
governed by established standards of clinical trials [6]
with appropriate trial structure and logistics. They
should be based on prospectively declared, detailed pro-
tocols written according to ethical standards. It is rec-
ommended [7] that, at this stage, measures of success
should not be focused on necessarily reaching statistical
significance in explorative efficacy signals. Exceptions
are safety readouts. They should be the primary end-
point together with feasibility readouts to inform further
steps. Like in drug trials, positive phase II stem cell stud-
ies with surrogate endpoints do not lead to approval and
adoption. They should produce datasets of foundational
benefit and safety, justifying subsequent studies with
clinically relevant objectives. This stepwise process
should ensure that only the safest products with the
strongest signals of efficacy move forward to clinical
testing in larger populations within definitive phase III
trials.Table 1 Stem cell clinical trials in patients with chronic heart failure
Trial N Cell type Delivery Timing post-
MAGIC37 [39] 97 SM Epicardial >4 weeks
Dib et al. [40] 23 SM Endocardial >10 years
SEISMIC11 [12] 47 SM Endocardial Chronic
TOPCARE-CHD [41] 121 BM-derived
progenitor cells
Coronary Chronic




FOCUS-CCTRN [42] 92 BMMNC Endocardial >30 days
POSEIDON [22] 30 MSC Endocardial >60 days
Poglajen et al. [43] 33 CD34+ Endocardial >6 months
SCIPIO [44] 33 c-kit + CSC Coronary >4 months
after CABG
TAC-HFT23 [24] 65 BMMNC, MSC Endocardial Ischemic
cardiomyopa
BM bone marrow, BMMNC bone marrow mononuclear cell, CABG coronary artery by
ventricular ejection fraction, LVESV left ventricular end-systolic volume, MLHFQ Minn
imaging, MSC mesenchymal stem cell, NTproANP amino-terminal pro-atrial natriuret
myoblasts, SPECT single-photon emission computed tomographySpecific considerations for design of regenerative trials
Currently, patient-derived stem cells are the primary
source for cardiac regenerative therapy [8–10]. Given
the specifics of stem cell-based intervention, phase I tri-
als are not meaningful in healthy volunteers and initial
feasibility and safety profiles are obtained in a limited
number of patients, comparable with other phase I/II
trials. At this stage, robust and independently validated
pre-clinical information data sets on safety and efficacy
should be available and should include stringent product
release criteria. Cell product characteristics, such as sta-
bility, potency, purity and mechanisms of cell action, as
well as cell line production (efficiency, cost, and compli-
ance) should also have been systematically addressed.
Selected previous trials in patients with ischemic heart
failure which have included more than 20 patients are
reviewed in Table 1. Early experience with cell-based in-
terventions was initially gathered with skeletal myo-
blasts. This cell type has been abandoned due to safety
concerns related to increased risk of cardiac arrhyth-
mias. Ongoing clinical programs typically utilize adult
progenitor cells derived from outside the heart (for ex-
ample, bone marrow) or from the heart, either autologous
or allogeneic, in naïve form or guided for optimized effi-
cacy [11]. Traditionally, left ventricular ejection fraction
(LVEF) has been the most common surrogate endpoint in
these trials. However, its assessment varied among the tri-
als and relied on multiple methods, including transtho-
racic echocardiography, left ventricular (LV) angiographyinfarction Primary endpoint
No change LVEF
Improved LVEF and viability
No change LVEF, improved 6-min walk
distance at 6 months
Improved survival and decreased levels of
NTproBNP and NTproANP in patients who received cells
thy
Safety/feasibility, improved LVEF by echo and
6-min walk distance
No changes in LVESV index and maximal oxygen
consumption (VO2max) by SPECT
No changes in LVEF by echo; improvement in 6-min walk
test, MLHFQ in autologous group
Increase in LVEF, 6-min walk distance and a decrease in
NTproBNP
Increase in MRI LVEF after 4 and 12 months and decrease of
infarct size after 4 and 12 months
thy
Improved 6-min walk distance, regional myocardial function
and decreased infarct size after 1 year (MRI or CT) in MSC group,
but not in BMMNC or placebo group
-pass graft surgery, CSC cardiac stem cell, CT computed tomography, LVEF left
esota Living with Heart Failure Questionnaire, MRI magnetic resonance
ic peptide, NTproBNP N-terminal pro-brain natriuretic peptide, SM skeletal
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note that few studies [12] have reported improvement in
clinical surrogate parameters without major changes in
cardiac function, emphasizing the need for the compre-
hensive assessment of efficacy signals where the cumu-
lative evidence rather a single endpoint may drive the
design of the ensuing clinical translation. Detailed analysis
of the field and future leads for clinical translation are pro-
vided elsewhere [11].
Relevant to the design is the choice of the delivery
method. Each delivery method has its merits and limita-
tions and should consider the cell type under study [13].
Coronary cell transfer relies on cell adhesion during
transmicrovascular migration leading to homogenous
myocardial distribution. On the other hand, it is associ-
ated with low rates of cell retention and cannot be used
with mesenchymal cells or skeletal myoblasts due to risk
of microvascular obstruction [14]. Direct myocardial de-
livery using the epicardial or endomyocardial route offer
higher rates of retention compared with the coronary
mode of delivery [15]. In the current trials, LV endomyo-
cardial injection is the preferred mode of delivery as it
can be performed as a standalone procedure. Moreover,
modes of enhanced cell delivery are continuously being
redesigned [16].
Myocardial engraftment is dependent on a number of
additional factors, including local environment, supply
of nutrients, immune rejection or co-transfer of support-
ing cell types, such as fibroblasts or endothelial cells,
hydrogels or matrix components [17, 18]. As the current
modes of delivery have so far led to suboptimal retention
rates [19] or limited long-term cell survival [20], data on
retention using specific cell types and methods of deliv-
ery should be obtained in the early stages to determine
the pharmacokinetics of the given cell product. This, to-
gether with the dose-escalation response, should help to
devise the optimal delivery strategy, maximizing the
chance for efficacy in ensuing trials while retaining the
favorable safety profile. Specific consideration is needed
regarding the targeting of injections into specifically desig-
nated areas when using endomyocardial delivery. On one
hand, electromechanical guidance as facilitated by the
NOGA® Cardiac Navigation System (Biologics Delivery
Systems Group, Irwindale, CA, USA) allows precise loca-
tion of the dysfunctional but viable myocardium. On the
other hand, pragmatic approaches with echocardiography
or fluoroscopic guidance of the endomyocardial delivery
have demonstrated encouraging efficacy signals within
several programs [21, 22], supporting pre-clinical obser-
vation of cell migration after myocardial delivery [23].
Standardization of the delivery techniques may help to
compare the efficacies of various cell types as indicated
from the recent comparison of endomyocardial delivery of
mesenchymal and mononuclear cells [24].The European Medicines Agency has released a state-
ment [25] covering specific aspects related to stem cell-
based products for which marketing authorization is
being sought. In first-in-man studies, specific safety end-
points may need to be defined based on theoretical con-
siderations and to detect early any toxicity of the final
cell product. In cases where sufficient safety evidence can-
not be established in the preclinical studies - for example,
due to difficulties in finding an appropriate animal model
- the evidence should be generated in clinical trials by in-
cluding additional endpoints for efficacy and safety. The
need for and duration of post-authorization long-term
efficacy follow-up should also be identified during the
clinical trials, taking into consideration results from non-
clinical studies and the intended therapeutic effect. In the
US, the FDA has postulated that cells or tissues used for
therapeutic purposes are codified under the Good Tissue
Practice. Consequently, FDA issued guidance about how
the biologic and device regulations apply to cellular and
genetic therapies [26]. Accordingly, investigational new
drug application necessitates detailed study protocols de-
scribing the clinical plan as well as the preparation and
testing of the therapeutic cell product.
Endpoints in ischemic heart failure phase I and II
trials
General requirements and safety/efficacy profiles for
phase I, II and III trials are summarized in Table 2. The
primary objective of all initial studies is to establish the
safety profile. The European Society of Cardiology Stem
Cell Task Group [27] proposed that initial safety read-
outs should focus on the risk of tissue injury or abnor-
mal growth and the possibility of arrhythmias, requiring
Holter monitoring or interrogation of an implantable
cardioverter/defibrillator in heart failure. Initial experience
should also focus on gathering information on the key
pharmacodynamic and pharmacokinetic features of regen-
erative therapy, which may include assays addressing
the mechanistic action, potency, interaction with disease
markers, and dependency on the mode of administration.
Cell therapy may be associated with challenges in each of
these areas that are distinct from traditional pharmaco-
logic therapies. For example, the component of a cell
product which contributes to efficacy and from which a
dose–response could be established is often unknown, and
potency can be quite variable and difficult to quantify. As
alluded to earlier, dose dependency of the safety profile
should be addressed in parallel to the explorative analysis
of the efficacy signals.
Consistent with the role of phase I/II studies in the
regulatory path, the sample size or power of the trial
should not be based on efficacy signals but instead
on the cohesive spectrum of projected endpoints that
are likely to be improved by the intervention or by
Table 2 Requirements and safety/efficacy profile recommendations for phase I, II and III trials
Preclinical, phase I Phase II Phase III
Product-regulatory
requirements
Kinetics, biodistribution of the cells.
Purity, potency and karyotype
stability of particular cells. Ensure
traceability
Short-term side effects and risk
associated with particular cell-based
biologics
Performed after preliminary evidence
suggesting effectiveness of particular cells





Identify potential responders and
non-responders
Include only responders
Sample size Usually 20 per cohort From a few dozen to a few
hundred
Several hundred or more
Design Randomized, open label or
placebo





activity of the cells
Safety/feasibility of the procedure,
adequate number of cells/dose
response
Long-term, substantial evidence of previously
observed feasibility/safety
Safety endpoints Patient tolerance, abnormal
cell growth, mutagenesis,
tumorigenicity
Patient tolerance, tissue injury,
possibility of arrhythmias
Clinically relevant objective: death, clinical events
Efficacy endpoints Detect surrogate endpoints
sensitive to track the therapeutic
benefit
1) Further analysis of previously
detected surrogate endpoints
2) Exploratory analysis of clinically
relevant endpoints
1) Clinically relevant endpoints. Objective (single
or composite): improved survival, reduced clinical
events/number of hospitalizations. Subjective:
symptom score, health-related quality of life
2) Surrogate efficacy endpoints that meaningfully
correlate with clinical endpoints
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cade of heart failure. It is critical not to overemphasize
individual outcomes of surrogate endpoints, but rather
to look at the totality of evidence they provide about the
potential clinical benefit. Given the limited number of
patients and focusing on safety/feasibility readouts, posi-
tive phase II studies do not lead to approval and wide-
spread clinical use, but instead produce subsequent
studies by providing foundational evidence and generat-
ing hypotheses. Surrogate endpoints are generally ac-
ceptable to evaluate biologic plausibility and feasibility in
these early trials, and to aid in hypothesis development
for larger phase III studies. Surrogate endpoint parame-
ters used to assess the effects of stem cell therapy on
survival in chronic ischemic heart disease should be able
to address the safety of cell-based intervention and
closely correlate with survival such that changes should
reflect changes in the prognosis, and there should be a
pathophysiological basis for both relations.
The latter is particularly important as positive results
in surrogate endpoint parameters supported by a known
pathophysiological basis can be viewed as a probability
signal to achieve the later clinical benefit [28–30] and
thus provide scientific/mechanistic support to formulate
the hypothesis in the pivotal phase III trial [30]. In other
words, surrogate endpoints in phase II trials serve as
proof-of-concept and provide preliminary evidence of
safety and efficacy.
The surrogate endpoint parameters typically used in
stem cell trials in chronic heart failure should includeendpoints from various domains reflecting target organ
changes within the clinical context: measures of LV
function and structural evaluation (that is, ejection frac-
tion, end-systolic and end-diastolic volumes and dimen-
sions, pressure-volume relationships, stroke volumes and
indexes, ventricular sphericity, infarct scar, perfusion defect,
ischemia); biomarkers reflecting the presence and severity
of disease (for example, natriuretic peptides, cardiac en-
zymes, C-reactive protein, cytokines); functional capacity
and symptoms relevant to the clinical setting (for example,
6-minute walking distance, maximal O2 consumption, ven-
tilatory efficacy/rate of elimination of carbon dioxide slope,
New York Heart Association (NYHA) class, angina score);
patient-reported outcome, such as quality of life question-
naires, dyspnea and NYHA class alone or in combination.
In these phase I/II trials all surrogate endpoints
should be complemented by observational analysis of
clinical outcomes related to the given setting and typ-
ically include mortality and cardiovascular morbidity,
including myocardial (re)infarction, stroke and un-
planned hospitalization due to acute heart failure. As
phase I/II cell trials are often unblinded, analysis of
all-cause safety endpoints (especially all-cause mortal-
ity) may reduce possible bias in those trials [30]. In
addition to these clinical safety readouts, local assess-
ment of the cell therapy with regard to cell delivery,
such as assessment of myocardial damage and myo-
cardial tissue changes, should be part of the global
safety assessment. Taken together, phase II studies
should aim to demonstrate concordance in surrogate
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for the hypothesis in the phase III trial.
Clinically relevant changes in surrogate endpoint
parameters
In ischemic chronic heart failure, the goal is to track the
impact on LV remodeling and function. The assessment
of ventricular remodeling (that is, characteristic changes
in ventricular volumes and wall thickness and shape,
ventricular sphericity, pressure-volume loops) could
point to positive effects of stem cells in chronic heart
failure. As remodeling may lead to a parallel decline in
systolic and diastolic volumes, it is possible that LVEF
may show only minor, non-significant changes. Changes
in LVEF should be evaluated in parallel with other surro-
gate endpoints such as exercise tolerance or changes in
humoral biomarkers. In this regard, lessons should be
taken from previous studies addressing the benefits of
positive inotropic drugs showing that improved cardiac
function did not translate into clinical benefit. On the
other hand, clinical benefit may be detected despite no or
minimal change in LV function. Thus, the continuation of
the clinical path in the early stages is determined by the
synergy between the observed surrogate signals and mech-
anisms leading to this observed improvement. The clinical
safety readouts, including mortality, heart failure admis-
sions or occurrence of life-threatening arrhythmia (that is,
ventricular tachycardia/ventricular fibrillation), remain the
primary safety endpoint. Recommendations for clinically
relevant changes in surrogate endpoints in ischemic heart
failure trials are given in Table 3.
Although the investigators of a phase II study may not
be able to predict a priori how big the effect will be (for
example, a change in LVEF), they certainly should be ex-
pected to determine the extent of the effect in the end.
In addition, a comparison between observed versus ex-
pected changes in different surrogate parameters might be
one of the best measures of the success of a phase II trial.
cMRI emerged as the gold standard for evaluation of
various surrogate endpoints, including cardiac volumes,
perfusion and structure. cMRI with late gadolinium en-
hancement is a powerful tool to determine the scar bur-
den and viability of the dysfunctional myocardium. It
can reliably assess the extent of remodeling and fibrosis,
and serve as a suitable tool to monitor myocardial
changes after stem cell therapy [31]. Myocardial strainTable 3 Clinically meaningful response in surrogate endpoints in isc
Symptoms Functional domain LV function remodel
A change in
NYHA class
a) Increase of 50 m in 6-min walk test
b) Increase of 10 % in VO2max
a) Increase of 5 % in
20 mL or 20 % (whic
in NTproBNP by 35 %
KCCQ Kansas City Cardiomyopathy Questionnaire, LV left ventricular, LVEF left ventr
MLHF Minnesota Living with Heart Failure Questionnaire, NTproBNP N-terminal pro-
maximal oxygen consumptioncalculated from cMRI tagging is currently regarded as
the non-invasive gold standard for assessment of re-
gional function [32]. In addition, cMRI enables analysis
of metabolic function, such as detection of high-energy
phosphate metabolism and blood-oxygen tension deter-
mination using blood oxygen level-dependent MRI [33].
Yet, despite being a key method to track the surrogate
endpoints [34], widespread use of MRI may be limited
by implanted devices.
Ischemic heart failure and phase III/IV stem cell
trials
Phase III trials are conventionally randomized, placebo-
controlled, double-blind and designed to generate defini-
tive conclusions about the clinical merits of the applied
method. Pivotal phase III trials are meant to provide
crucial facts about whether the intervention meaning-
fully improved the quality of life and decreased cardio-
vascular morbidity and mortality in order to support
regulatory approval. Phase III trials must be clinically
driven, emphasizing hard clinical endpoints starting with
all-cause mortality/cause-specific mortality [21]. Then,
depending on the clinical setting, endpoints include car-
diovascular improvement/deterioration, including re-
infarction and need for revascularization, life threatening
arrhythmias and worsening heart failure. The choice of
either all-cause mortality or cardiovascular mortality is
still under debate [35]. While all-cause mortality may
appear more relevant from the regulatory perspective, it
is associated with random noise, diluting the therapeutic
impact in high risk patients such as heart failure pa-
tients. In this particular setting, non-cardiovascular mor-
tality is increased due to aging or co-morbidities and
cardiovascular mortality may be preferred over the all-
cause mortality [35]. Nevertheless, in stem cell clinical
trials all-cause mortality should serve as a safety readout
and should be directionally concordant or at least neu-
tral with the eventual improvement in cardiovascular
mortality. The heart failure population remains the most
challenging target for cell therapy also from the perspec-
tive of tracking worsening heart failure and hospitaliza-
tions [34] due to regional differences in health care
policies and local standards in patient management.
In addition, not all hospitalizations necessarily indicate
worsening heart failure and, at times, can be seen as an
opportunity to optimize overall patient management.hemic heart failure trials
ing Quality of life
absolute LVEF or; b) Decrease of
hever is greater) in LVESV c) Decrease
or 300 pg/ml, whichever is greater
a) Improvement in MLHF-Q ≥10
b) Improvement in KCCQ ≥20
icular ejection fraction, LVESV left ventricular end-systolic volume,
brain natriuretic peptide, NYHA New York Heart Association, VO2max,
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Cardiology proposed in its consensus to define heart fail-
ure hospitalization as at least an overnight stay in hospital
caused by substantive worsening of heart failure symp-
toms and/or signs requiring the augmentation of intraven-
ous heart failure therapy, including inotropes, diuretics or
vasodilators, ideally pre-defined in the critical events man-
ual [34]. Similar to endpoints using cardiovascular mortal-
ity, tracking non-heart failure hospitalizations is also of
interest as their reduction or increase concordant with
heart failure admissions provides safety reassurance and
strengthens the findings of the cardiac-related endpoints.
To determine the sample size for any pivotal trial of
cell therapy requires knowledge of the event rates antici-
pated in the control group based on the standard of care
and an estimate of the reduction likely to be achieved by
the intervention based on the surrogate efficacy signals
from phase II. For example, in a population with ad-
vanced heart failure in which the probability of death or
heart failure worsening in the course of a year is 35 %,
an intervention anticipated to reduce the event rate by
50 % would require 330 patients for a trial with 90 %
power to detect the difference at an alpha of <0.01 %.
The number of patients that must be enrolled rises to
1,500 if the intervention is expected to reduce the event
rate by only 25 %. In addition, if primary endpoint is all-
cause mortality, rather than cardiovascular mortality, the
sample size will need to be larger to account for the
‘random noise’ added by other deaths due to associated
co-morbidities. Such numbers can be reduced by ma-
neuvers such as defining composite endpoints that in-
clude classifying patients into categories of improved,
unchanged or worse, or by an adaptive design. Though
instrumental in predicting estimated rates of events, the
standard of care is a dynamic process and projected
event rates based on previous published data may often
be different at the time of trial execution. This can ham-
per the expected enrollment rates or be associated with
lower than expected numbers of events, leading poten-
tially to trial termination. So far, these risks are not suffi-
ciently considered in chronic heart failure, but in
patients with chronic myocardial ischemia or critical
limb ischemia, for example, improvements in the stand-
ard of care and technology appear to have reduced the
pool of patients previously qualifying for cell therapy
interventions.
As in phase II studies, the design and control arm are af-
fected by the clinical setting and delivery technique and
earlier findings within specific programs. On the other
hand, the quality of blinding at this stage is crucial for the
critical objective evaluation of clinical endpoints such as
quality of life, as well as endpoints such as re-admissions/
re-hospitalizations. The blinding and placebo-controlled
design can be ethically challenging in cell trials utilizingdirect myocardial delivery. In such cases, sham-controlled
procedures coupled with a strict separation of unblinded
procedural/operational and blinded clinical teams could
be considered as an alternative to the standard double-
blinded, placebo-controlled design. Additional challenges
for the adjudication of clinical events, such as re-
admissions, are differences in local clinical practices and
increasing economic pressure causing heterogeneity in the
rates of admission for otherwise similar clinical presenta-
tion. The timing of obtaining the primary endpoint should
also be carefully considered in the context of the target
population and expected rates of clinical events. Typically,
one-year follow-up is the most meaningful time interval;
this timing can be shortened if the patient population is
enriched to include patients with advanced disease.
Composite endpoints in ischemic heart failure
phase III stem cell trials
Considering that individual ‘hard’ endpoints often re-
quire large trials and lack statistical power when insuf-
ficient numbers of patients are included, composite
endpoints might provide an acceptable alternative to as-
sess the clinical effect of cell intervention. A composite
outcome can prove helpful, enabling early clinical adop-
tion in high risk populations or populations with unmet
need, as was demonstrated by the initial cardiac resyn-
chronization therapy regulatory approval. Appropriate a
priori identification of composite endpoints can increase
the statistical precision and efficiency of trials and make
them less costly. In addition, a composite outcome may
be helpful in situations where it is difficult to decide
which outcome to elect as the primary clinical outcome
measure by using a combination of various readouts from
various domains. However, a caveat should be in place as
adding more components should not make interpretation
of the results complex. At the same time, essential mea-
sures of composite outcome should incorporate mortality,
morbidity and patient-reported outcome.
A typical positive example of composite endpoint use in
a phase III trial is the CAPRICORN study [36], where an
important component of the composite outcome was not
substantially modified and the combination of several
endpoints proved the superiority of the active treatment. A
fundamental condition for composite outcome is that indi-
vidual outcomes contributing to a composite outcome have
to be associated with the primary objective. Likewise, their
analysis should be done in the hierarchical order where the
most significant clinical outcome cancels out any other
outcome that is clinically less significant. Moreover, the
limitation in terms of different clinical significance of the
observed individual endpoints may be leveled by a pre-
defined analytical plan giving varying (hierarchical) weight
to the components; for example, cardiovascular death 1,
re-infarction 0.5, and target vessel revascularization 0.1.
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values to each endpoint could be debated, the method-
ology of hierarchical composite endpoints can reduce
the sample size needed to show efficacy compared with
a single clinically related endpoint. The Finkelstein and
Schoenfeld analytical plan of hierarchical evaluation may
serve as an example [37]. For instance, a trial incorpo-
rates various events, such as all-cause death, heart failure
events, change in 6-minute walk distance and changes in
LVEF or end-systolic volumes. The analysis is based on a
hierarchy of endpoints and is constructed by comparing
every subject in the active arm with every subject in the
comparator arm and assigning +1, 0, −1 scores depend-
ing on whether the subject in the treatment arm did bet-
ter, the same or worse. These scores are assigned at the
designated time of the primary readout, for instance, at
52 or 104 weeks. In case of mortality, days alive out of
the designated time period or number of heart failure
events are counted; using a pre-specified cutoff value,
other readouts are categorized as meaningful improve-
ment, deterioration or no meaningful change. Mortality
is evaluated first. If both died, the one dying later did
better. If only one died, the one surviving did better. If
neither died, the next point in the hierarchy is evaluated.
The one with less heart failure events did better. If they
are similar, lower endpoints in the hierarchy, such as 6-
minute walk distance, are evaluated. Subjects tied in all
these endpoints will then be evaluated for other end-
points, such as volumes or ejection fraction. In the final
step, treatment groups are compared using a test statis-
tic based on the sum of net scores for all subjects.
Hence, the choice of individual endpoints from which
to compose the hierarchical analytical tree should be
based on several considerations: does the composite
endpoint measure the severity of the disease - does it
cover its critical components? Can its use solve the med-
ical problem or is it just a statistical convenience? Are
the individual parameters valid, biologically plausible
and of importance to patients? Are the final results clear
and meaningful, do they provide a basis for therapeutic
decision, does each endpoint support the overall result
and do they indicate/predict improved mortality (based
on state-of-the-art knowledge)?
Composite endpoints in heart failure trials with stem
cells may include cardiovascular death, re-infarction,
worsening of heart failure with repeat hospitalizations or
intravenous treatment, target vessel revascularization,
stroke, implantable cardioverter device therapy, and heart
transplantation. Cardiovascular death includes death
resulting from an acute myocardial infarction, sudden car-
diac death, death due to heart failure, death due to stroke,
and death due to other cardiovascular causes, including
unwitnessed death without other cause of death. It is also
important to emphasize that a complex combination ofobjective measures of mortality/morbidity with subjective
measures (NYHA class) or mechanistic endpoints (that is,
brain natriuretic peptide) are difficult to interpret and thus
are generally discouraged.
Future trends
As our knowledge about cardiac stem cell therapies im-
proves, insight into the significance of patient-specific
disease management grows. In many cases it will be ne-
cessary to tailor the endpoints to meet the needs of the
studied population. In this regard, systematic stratifica-
tion of patients to adequately match clinical trials will be
of paramount importance. Therefore, emphasis should
be on delineating acute versus chronic disease and allo-
geneic versus autologous transplantation, identifying re-
sponders and non-responders as well as pre-treatment
of co-morbidities to limit modifiable confounding fac-
tors; this is especially important for stem cell treatment.
In every case, hard clinical endpoints stay the necessity
for future clinical cell trials, but standardization of out-
come measures, choice of cells and cell manufacturing
remain an imposed standard in the trial design. Stan-
dards of efficacy need to be established as continuous
improvements in standard of care lead to better quality of
life and survival; likewise, regional differences in health
care policies need to be considered as they may impact
the assessment of readouts such as readmissions [25].
Another aspect to consider in the design of trials is
the increasing financial cost needed for funding large
clinical trials required to demonstrate the added value of
newly tested treatments. At the same time, increased
socio-economic pressure forces physicians and health-
care providers to shift care towards outpatient care or
care in the patient’s home and new endpoints reflecting
this change in socio-economic and healthcare policies
should be considered. In this regard, endpoints based on
socio-economic evaluations using parameters such as
benefit expressed in terms of quality-adjusted life years
might be of help [38]. In this regard, a Markov decision
analysis model to calculate the incremental cost-
effectiveness ratio in cardiac stem cell trials might be help-
ful. Positive results in cost per life-year calculations gained
with stem cell treatment compared with no treatment
might persuade governments and encourage biotechnol-
ogy companies to further invest in stem cell trials.
Conclusion
As initial autologous stem cell-based cardiac regener-
ation therapy led to a rather rapid translation into early-
phase clinical trials, the research has now reached the
point where conclusive answers and thoughtful fine-
tuning are needed. Phase III, large-scale, multicenter,
double-blind (sham- controlled), randomized clinical tri-
als performed under rigorous safety standards are
Banovic et al. Stem Cell Research & Therapy  (2015) 6:159 Page 8 of 9necessary to confirm clinical benefits. In this regard,
consensus on clinical endpoints and methodologies used
to assess those endpoints are necessary to move forward
and critically examine the quality of data gathered in fu-
ture clinical investigations of cardiac stem cell therapy.
Abbreviations
cMRI: Cardiac magnetic resonance imaging; FDA: Food and Drug
Administration; LV: Left ventricular; LVEF: Left ventricular ejection fraction;
MRI: Magnetic resonance imaging; NYHA: New York Heart Association.
Competing interests
MV and JB are members of an institution which is a shareholder of Celyad.
AZ is a consultant to and co-founder of T2CURE. All other authors declare
that they have no competing interests.
Authors’ contributions
MB, JB: made substantial contributions to conception and design, drafting
the manuscript and revising it critically. MM: drafting the manuscript and
revising it critically. ZL, AB, MV, BB, AT, AZ: ensured that questions related to
the accuracy or integrity of any part of the work are appropriately
investigated and resolved; gave final approval of the version. All authors read
and approved the final manuscript.
Author details
1Cardiology Department, University Clinical Center of Serbia, Belgrade
Medical School, 11000 Belgrade, Serbia. 2Mayo Clinic, Rochester, MN 55905,
USA. 3Cardiovascular Center, OLV Hospital, 9300 Aalst, Belgium. 4Cardiology
Department, Goethe University of Frankfurt, 60590 Frankfurt, Germany.
5Cardiology Department, University of Brescia, 25123 Brescia, Italy.
Received: 2 February 2015 Revised: 2 June 2015 Accepted: 4 August 2015
References
1. Hanna BE, Hennebry TA, Abu-Fadel MS. Combined reperfusion strategies in
ST-segment elevation MI: rationale and current role. Clev Clin J Med.
2010;77:629–38.
2. Kovacic JC, Castellano JM, Fuster V. Cardiovascular defence challenges at
the basic, clinical, and populations level. Ann N Y Acad Sci. 2012;1254:1–6.
3. Bartunek J, Vanderheyden M, Hill J, Terzic A. Cells as biologic for cardiac
repair in ischemic heart failure. Heart. 2010;96:792–800.
4. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM.
Autologous bone marrow stem cells to treat acute myocardial infarction: a
systematic review. Eur Heart J. 2008;29:1807–18.
5. Abdel-Latif A, Bolli R, Tieyjeh IM, Montori VM, Perin EC, Hornung CA, et al.
Adult bone marrow- derived cells for cardiac repair: a systematic review and
meta analysis. Arch Intern Med. 2007;167:989–97.
6. Stanley K. Design of randomized controlled trials. Circulation. 2007;115:1164–9.
7. Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, et al. Phase II
clinical research design in cardiology: learning the right lessons too well:
observations and recommendations from the cardiovascular cell therapy
research network (CCTRN). Circulation. 2013;127:1630–5.
8. Behfar A, Crespo-Diaz R, Nelson TJ, Terzic A, Gersh BJ. Stem cells: clinical
trials results the end of the beginning or the beginning of the end?
Cardiovasc Hematol Disord Drug Targets. 2010;10:186–201.
9. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons
from the heart. Nature. 2008;453:322–9.
10. Hansson EM, Lindsay ME, Chien KR. Regeneration next: toward heart stem
cell therapeutics. Cell Stem Cell. 2009;5:364–77.
11. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ. Cell therapy for cardiac repair -
lessons from clinical trials. Nat Rev Cardiol. 2014;11:232–46.
12. Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A,
et al. Final results of a phase IIa, randomised, open-label trial to evaluate the
percutaneous intramyocardial transplantation of autologous skeletal
myoblasts in congestive heart failure patients: the SEISMIC trial.
Eurointervention. 2011;7:805–12.
13. Bartunek J, Sherman W, Vanderheyden M, Fernandez-Aviles F, Wijns W,
Terzic A. Delivery of biologics in cardiovascular regenerative medicine.
Clin Pharmacol Ther. 2009;85:548–52.14. Furlani D, Ugurlucan M, Ong L, Bieback K, Pittermann E, Westien I, et al. Is
the intravascular administration of stem cells safe? Mesenchymal stem cells
and intravital microscopy. Microvasc Res. 2009;77:370–6.
15. Kandala J, Upadhyay GA, Pokushalov E, Wu S, Drachman DE, Singh JP.
Meta-analysis of stem-cell therapy in chronic ischemic cardiomyopathy.
Am J Cardiol. 2013;112:217–25.
16. Behfar A, Latere JP, Bartunek J, Homsy C, Daro D, Crespo-Diaz RJ, et al.
Optimized delivery system achieves enhanced endomyocardial stem cell
retention. Circ Cardiovasc Interv. 2013;6:710–8.
17. Prowse ABJ, Timmins NE, Yau TM, Li RK, Weisel RD, Keller G, et al.
Transforming the promise of pluripotent stem cell-derived cardiomyocites
to a therapy: challenges and solutions for clinical trials. Can J Cardiol.
2014;30:1335–49.
18. Wu J, Zeng F, Huang XP, Chung JC, Konecny F, Weisel RD, et al. Infarct
stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel.
Biomaterials. 2011;32:579–86.
19. Dib N, Khawaja H, Warner S, McCarthy M, Campbell A. Cell therapy for
cardiovascular disease: a comparison of methods of methods of delivery.
J Cardiovasc Transl Res. 2011;4:177–81.
20. Van Laake LW, Passier R, Monshouwer-Kloots J, Verkleij AJ, Lips DJ, Freund C,
et al. Human embryonic stem cells-derived cardiomyocites survive and
mature in the mouse heart and transiently improve function after
myocardial infarction. Stem Cell Res. 2007;1:9–24.
21. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J,
et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE
(Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized
trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61:2329–38.
22. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP,
Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-
derived mesenchymal stem cells delivered by transendocardial injection in
patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
JAMA. 2012;308:2369–79.
23. Zhang H, Song P, Tang Y, Zhang X-I, Zhao S, Wei Y, et al. Injection of bone
marrow mesenchymal stem cells in the borderline area of infracted myocardium:
heart status and cell distribution. J Thorac Cardiovasc Surg. 2007;134:1234–40.
24. Heldman AW, DiFede DL, Fishman JL, Zambrano JP, Trachtenberg BH,
Karantalis V, et al. Transendocardial mesenchymal stem cells and
mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-
HFT Randomized Trial. JAMA. 2014;311:62–73.
25. George B. Regulations and guidelines governing stem cell based products:
clinical considerations. Perspect Clin Res. 2011;2:94–9.
26. US Food and Drug Administration, Center for Biologics Evaluation and
Research. Guidance for human somatic cell therapy and gene therapy. 1998.
[http://www.fda.gov/BiologicsBloodVaccines/GuidanceCompliance
RegulatoryInformation/Guidances/CellularandGeneTherapy/ucm072987.htm].
27. Bartunek J, Dimmeler S, Drexler H, Fernandez-Aviles F, Galinanes M,
Janssens S, et al. The consensus of the task force of the European Society of
Cardiology concerning the clinical investigation of the use of autologous
adult stem cells for repair of the heart. Eur Heart J. 2006;27:1338–40.
28. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA,
Udelson JE. Quantitative evaluation of drug or device effects on ventricular
remodeling as predictors of therapeutic effects on mortality in patients with
heart failure and reduced ejection fraction: a meta-analytic approach. J Am
Coll Cardiol. 2010;56:392–406.
29. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left
ventricular end-systolic volume as the major determinant of survival after
recovery from myocardial infarction. Circulation. 1987;76:44–51.
30. Wittes J, Lakatos E, Probstfield J. Surrogate endpoints in clinical trials:
cardiovascular diseases. Stat Med. 1989;8:415–25.
31. Klein C. Magnetic resonance imaging and positron emission tomography as
predictors of heart failure. Heart Metab. 2009;42:15–20.
32. Hopp E, Lunde K, Solheim S, Aakhus S, Arnesen H, Forfang K, et al. Regional
myocardial function after intracoronary bone marrow cell injection in
reperfused anterior wall infarction - a cardiovascular magnetic resonance tagging
study. J Cardiovasc Magn Reson. 2011;13:22. doi:10.1186/1532-429X-13-22.
33. Fuster V, Sanz J, Viles-Gonzalez JF, Rajagopalan S. The utility of magnetic
resonance imaging in cardiac tissue regeneration trials. Nat Clin Practice
Cardiovasc Med. 2006;3:S2–7.
34. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in
sample size for studies of remodeling in heart failure by the use of
cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2000;2:271–8.
Banovic et al. Stem Cell Research & Therapy  (2015) 6:159 Page 9 of 935. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, et al.
Clinical end-points in heart failure trials: a European Society of Cardiology
Heart Failure Association consensus document. Eur J Heart Fail.
2013;15:1082–94.
36. Dargie H. Effect of carvedilol on outcome after myocardial infarction in
patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Lancet. 2001;357:1385–90.
37. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal
measures in clinical trials. Stat Med. 1999;18:1341–54.
38. Costa V, McGregor M, Laneuville P, Brophy JM. The cost-effectiveness of
stem cell transplantations from unrelated donors in adult patients with
acute leukemia. Value Health. 2007;10:247–55.
39. Kang H-J, Kim H-S, Zhang S-Y, Park K-W, Cho H-J, Koo B-K, et al. Effects of
intracoronary infusion of peripheral blood stem-cells mobilised with
granulocyte-colony stimulating factor on left ventricular systolic function
and restenosis after coronary stenting in myocardial infarction: the MAGIC
cell randomised clinical trial. Lancet. 2004;363:751–6.
40. Dib N, Dinsmore J, Lababidi Z, White B, Moravec S, Campbell A, et al.
One-year follow-up of feasibility and safety of the first U.S., randomized,
controlled study using 3-dimensional guided catheter-based delivery of
autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC
study). JACC Cardiovasc Interv. 2009;1:9–16.
41. Assmus B, Fischer-Rasokat U, Honold J, Seeger FH, Fichtlscherer S, Tonn T,
et al. Transcoronary transplantation of functionally competent BMCs is
associated with a decrease in natriuretic peptide serum levels and
improved survival of patients with chronic postinfarction heart failure:
results of the TOPCARE-CHD Registry. Circ Res. 2007;100:1234–41.
42. Perin E, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DXM, et al. Effect of
transendocardial delivery of autologous bone marrow mononuclear cells on
functional capacity, left ventricular function, and perfusion in chronic
ischemic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307:1717–26.
43. Poglajen G, Sever M, Cukjati M, Cernelc P, Knezevic I, Zemljic G, et al. Effects
of transendocardial CD34+ cell transplantation in patients with ischemic
cardiomyopathy. Circ Cardiovasc Interv. 2014;4:552–9.
44. Bolli R, Chugh AR, D’Amario D, Loughran JH, Stoddard MF, Ikram S, et al.
Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO):
initial results of a randomised phase 1 trial. Lancet. 2011;378:1847–57.
